Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ONCT)

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

GlobeNewswire 6 hours ago

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 1 day ago

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire April 18, 2024

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

GlobeNewswire March 15, 2024

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 7, 2024

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 29, 2024

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 6, 2024

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 1, 2024

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire January 8, 2024
View More News ››

Opinion & Analysis (NDAQ:ONCT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ONCT)

ONCT announced stock split 1-20

Just In: $ONCT ONCT announced stock split 1-202024-01-08 08:02:08 ET Oncternal Therapeutics Inc (ONCT) announced stock split at a ratio...
whytestocks - January 8, 2024

GTX Inc Del Options

On 01/23/09 GTX Inc Del options ( GTXI ) are used as an example of market neutral investing on PERSONALHEDGEFUNDS.COM. Hedge fund...
nickmessaro02 - January 23, 2009
View more Bullboard ››

Royalties Inc.

Royalties Inc.

Royalties Inc. is focused on seeking cash flow generating royalty opportunities in various industries. While the Issuer’s ...
View More »